Compare Stocks → [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ARYDNASDAQ:CERONASDAQ:FHLTNASDAQ:PRE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARYDARYA Sciences Acquisition Corp IV$11.42+0.2%$11.31$10.45▼$11.42$86.11M-0.0142,753 shs208 shsCEROCERo Therapeutics$1.06-3.6%$1.74$1.03▼$12.80$15.61M-0.08808,656 shs62,475 shsFHLTFuture Health ESG$10.96-7.5%$11.56$10.10▼$15.05$65.10M-0.126,258 shs1,443 shsPREPrenetics Global$6.07+4.7%$4.55$2.85▼$15.00$55.48M-0.2892,079 shs13,776 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARYDARYA Sciences Acquisition Corp IV+0.18%+0.44%+0.97%+1.78%+9.39%CEROCERo Therapeutics-3.64%-8.62%-29.33%-74.64%+105,999,900.00%FHLTFuture Health ESG-7.51%-1.26%+2.14%+3.10%+7.98%PREPrenetics Global+4.58%-2.41%+109.31%+19.72%-55.96%Next President (Not Trump. Not Biden.) (Ad)Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump.Click here to see why it will be ______ _________.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARYDARYA Sciences Acquisition Corp IVN/AN/AN/AN/AN/AN/AN/AN/ACEROCERo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AFHLTFuture Health ESGN/AN/AN/AN/AN/AN/AN/AN/APREPrenetics Global1.2018 of 5 stars3.53.00.00.00.60.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARYDARYA Sciences Acquisition Corp IVN/AN/AN/AN/ACEROCERo TherapeuticsN/AN/AN/AN/AFHLTFuture Health ESGN/AN/AN/AN/APREPrenetics Global3.00Buy$9.0048.27% UpsideCurrent Analyst RatingsLatest FHLT, ARYD, PRE, and CERO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024PREPrenetics GlobalCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$10.00 ➝ $9.00(Data available from 5/21/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARYDARYA Sciences Acquisition Corp IVN/AN/AN/AN/A($3.49) per shareN/ACEROCERo TherapeuticsN/AN/AN/AN/AN/AN/AFHLTFuture Health ESGN/AN/AN/AN/A($1.56) per shareN/APREPrenetics Global$21.74M2.55N/AN/A$23.00 per share0.26Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARYDARYA Sciences Acquisition Corp IV-$2.13MN/A0.00∞N/AN/A-9.83%-5.41%N/ACEROCERo TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AFHLTFuture Health ESG-$50KN/A0.00∞N/AN/A-9.79%-0.28%N/APREPrenetics Global-$62.72M-$4.80N/A∞N/A-193.60%-11.15%-9.03%6/3/2024 (Estimated)Latest FHLT, ARYD, PRE, and CERO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023PREPrenetics GlobalN/A-$0.52-$0.52$0.53N/A$5.43 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARYDARYA Sciences Acquisition Corp IVN/AN/AN/AN/AN/ACEROCERo TherapeuticsN/AN/AN/AN/AN/AFHLTFuture Health ESGN/AN/AN/AN/AN/APREPrenetics GlobalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARYDARYA Sciences Acquisition Corp IVN/A0.010.01CEROCERo TherapeuticsN/AN/AN/AFHLTFuture Health ESGN/A0.020.02PREPrenetics GlobalN/A2.372.29OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARYDARYA Sciences Acquisition Corp IV48.08%CEROCERo Therapeutics29.64%FHLTFuture Health ESG24.57%PREPrenetics Global25.01%Insider OwnershipCompanyInsider OwnershipARYDARYA Sciences Acquisition Corp IV53.45%CEROCERo Therapeutics15.80%FHLTFuture Health ESG57.20%PREPrenetics GlobalN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableARYDARYA Sciences Acquisition Corp IV37.54 million3.51 millionNot OptionableCEROCERo Therapeutics814.72 million12.40 millionN/AFHLTFuture Health ESG2,0215.94 million2.54 millionNot OptionablePREPrenetics Global4009.14 millionN/ANot OptionableFHLT, ARYD, PRE, and CERO HeadlinesRecent News About These CompaniesMay 18 at 3:46 AM | americanbankingnews.comPrenetics Global (NASDAQ:PRE) Trading Down 0.8%May 17, 2024 | americanbankingnews.comContrasting Prenetics Global (NASDAQ:PRE) & Rapid Micro Biosystems (NASDAQ:RPID)April 26, 2024 | zawya.comAitrasound® Medical Group Announces Completion of a Pre-A Financing Round of Nearly 60 Million Hong Kong DollarsApril 26, 2024 | schaeffersresearch.comDow Down Triple Digits; Tesla Props Up NasdaqApril 6, 2024 | benzinga.comPrenetics Global Stock (NASDAQ:PRE), Analyst Ratings, Price Targets, PredictionsApril 3, 2024 | baystreet.caPrenetics Flat on Financial ResultsApril 1, 2024 | finanznachrichten.dePrenetics Global Limited: Prenetics Announces Fourth Quarter and Full Year 2023 Financial ResultsApril 1, 2024 | benzinga.comPrenetics Global: Q4 Earnings InsightsApril 1, 2024 | investorplace.comPRE Stock Earnings: Prenetics Global Beats EPS, Misses Revenue for Q4 2023April 1, 2024 | globenewswire.comPrenetics Announces Fourth Quarter and Full Year 2023 Financial ResultsFebruary 9, 2024 | finance.yahoo.comPrenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space StationFebruary 9, 2024 | globenewswire.comPrenetics Announces MOU for a Strategic Investment and 5-Year Research Collaboration with Metavisionaries to Pioneer R&D on the International Space StationJanuary 17, 2024 | msn.comPrenetics Global files to sell 1.48M Class A shares for holdersDecember 18, 2023 | investing.comPrenetics Global (PRE) Earnings Dates & ReportsDecember 17, 2023 | seekingalpha.comPRENW Prenetics Global Limited WT EXP 051827November 20, 2023 | benzinga.comPrenetics Global Stock (NASDAQ:PRE) Insider TradesNovember 20, 2023 | msn.comPrenetics Global GAAP EPS of -$0.08, revenue of $4.86MNovember 20, 2023 | benzinga.comPrenetics Global: Q3 Earnings InsightsNovember 20, 2023 | finance.yahoo.comPrenetics Announces Third Quarter 2023 Financial ResultsNovember 11, 2023 | finance.yahoo.comPrenetics Global Limited (NASDAQ:PRE): Is Breakeven Near?New MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Power Surge: Utilities Sector's Resilience ShinesApril 25, 2024 9:51 AMView Power Surge: Utilities Sector's Resilience ShinesBeyond the Halving: The Future of Bitcoin Mining StocksApril 23, 2024 9:50 AMView Beyond the Halving: The Future of Bitcoin Mining StocksHow to Buy the Dip and Sell the Rip on Your Stocks with OptionsMay 15, 2024 10:30 AMView How to Buy the Dip and Sell the Rip on Your Stocks with OptionsChinese Stocks Stage Impressive ReboundMay 6, 2024 7:45 AMView Chinese Stocks Stage Impressive ReboundAll HeadlinesCompany DescriptionsARYA Sciences Acquisition Corp IVNASDAQ:ARYDArya Sciences Acquisition Corp IV does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on acquiring North American or European companies in the life sciences and medical technology sectors. The company was incorporated in 2020 and is based in New York, New York.CERo TherapeuticsNASDAQ:CEROCERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.Future Health ESGNASDAQ:FHLTFuture Health ESG Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Dover, Delaware.Prenetics GlobalNASDAQ:PREPrenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies. In addition, the company, through its equity interests in ACT Genomics Holdings Company Limited, is involved in genomic profiling of solid tumors through ACTOnco. Prenetics Global Limited was founded in 2007 and is based in Quarry Bay, Hong Kong. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
